Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.
about
Topical pimecrolimus for eczemaSystemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patientsAn Alternative Approach to Atopic Dermatitis: Part II—Summary of Cases and DiscussionNonsteroidal Topical Immunomodulators in Allergology and DermatologyPimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infantsEfficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis.Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies.Pimecrolimus cream 1% in the management of atopic dermatitis in pediatric patients: a meta-analysisLong-term safety of tacrolimus ointment in children treated for atopic dermatitis.Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approachesNew insights into atopic dermatitis.Pimecrolimus for the treatment of inflammatory skin disease.Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.Atopic dermatitis disease control and age: A cohort study.The role of topical calcineurin inhibitors in atopic dermatitis.Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.The effect of TJ-15 plus TJ-17 on atopic dermatitis: a pilot study based on the principle of pattern identificationImmunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum.Problem-based learning: a review of current issues relevant to physiotherapy education.Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.A systematic review of the safety of topical therapies for atopic dermatitis.Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.Pimecrolimus versus topical corticosteroids in dermatology.Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.Warm, humid, and high sun exposure climates are associated with poorly controlled eczema: PEER (Pediatric Eczema Elective Registry) cohort, 2004-2012.Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.Pimecrolimus cream in the management of patients with atopic eczema.Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.How are eczema 'flares' defined? A systematic review and recommendation for future studies.Treatment of atopic dermatitis with pimecrolimus - impact on quality of life.Efficacy of topical azathioprine and betamethasone versus betamethasone-only emollient cream in 2-18 years old patients with moderate-to-severe atopic dermatitis: A randomized controlled trial.Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial.Study of the Atopic March: Development of Atopic Comorbidities.[Antipruritic effects of pimecrolimus and tacrolimus].
P2860
Q24243250-D5E65891-090A-40E7-A69A-708324A7B385Q24675365-C7C3D2FC-6CF2-4E4A-B0FB-107B58A5CD54Q24806074-9D47FAAF-9969-42AA-B0F1-104B21ADB486Q26752832-AC97FAAE-920E-454E-A576-8C4E5C332817Q28086973-864E420C-8213-4037-B7E3-C14A2E889D40Q31149849-863F02C5-30ED-481E-B4E7-68018A00868AQ34497913-DA039DE2-6707-4A66-A60A-12251E106C3AQ34552586-D585A5D2-01B5-4E49-A29D-273C156D8131Q35077866-09CA335A-CD1F-4472-93CA-BF669BEBAD15Q35106685-8CCA2820-4786-45D7-B7A3-E90EE5F5C745Q35137660-E3204DAB-C7B6-47A0-8F6C-B82A483CE133Q35208400-BECB2CC6-E47A-4B71-B8DA-8D1B35431921Q35603170-408610D5-C7BB-49EA-A261-0E2621823511Q35678332-66869452-0777-4262-8AA4-0E6F58CFB6DFQ35688189-6CD9AF3C-1DEE-465A-908C-C8FB42841620Q35809490-35A9C46D-75E5-4142-89D5-11D6E47F2FBDQ35828352-3C859CED-CEED-44DB-A734-96B9EBA9C72BQ35952647-ED7D133A-1C88-49F1-9D76-2813233D71DAQ36042131-9E402DB2-014B-493D-A606-D1048D0A89ADQ36079836-BF61AA23-8C30-4689-913C-E35A0160787BQ36222741-6FF8505E-00E6-4CCC-90F0-14BF30B00536Q36305883-9E97524C-E959-408D-B917-E5E6A528B20DQ36356956-328342DD-98FA-4784-BB01-1B56FC0CA9AFQ36574341-6093CF1E-1936-49BF-8DF5-C2B4C0247799Q36708358-74E3872B-E4F0-4E82-8940-650AAB522282Q36861654-B58C58A2-0ED2-4BDF-86D1-C026D1B82C1DQ36892767-77EE1611-3F71-4E88-8F9E-256A5C769969Q36895865-875B5020-0E0C-491A-9333-F9CDAD2692F9Q37049981-62F02BB2-423A-44CF-8112-4721E9DC1BBBQ37049990-A5916408-EA9C-4DFF-8E9F-6BC936386BF2Q37407574-2D8688CC-D4AB-4CE6-8DD8-0F6B5D4C0351Q37731539-81D55E8E-585C-4DA2-934E-42017DCB9EF7Q37857666-7FDF851E-5A6B-4F75-B4C9-1E57F14D17C7Q38123240-4F16C6B2-B22B-49D6-BB3F-2D38AFF73B88Q38165233-C96DC221-BB24-4CE7-9E91-342CFA2D6158Q38536150-51EF5E87-E93B-451B-9C52-75C242971D1AQ38936835-09E4081B-FCD7-42A1-8D1C-D204423EC78AQ39355978-0FC54538-06A5-43F0-8656-426909F69CEEQ40713406-0F31D5AC-06DE-45E3-BAB2-A2F4E1F035FEQ44420847-86B63A46-8E3A-4C1A-8790-E83D147C81C7
P2860
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Long-term management of atopic ...... teroid anti-inflammatory drug.
@ast
Long-term management of atopic ...... teroid anti-inflammatory drug.
@en
Long-term management of atopic ...... teroid anti-inflammatory drug.
@nl
type
label
Long-term management of atopic ...... teroid anti-inflammatory drug.
@ast
Long-term management of atopic ...... teroid anti-inflammatory drug.
@en
Long-term management of atopic ...... teroid anti-inflammatory drug.
@nl
prefLabel
Long-term management of atopic ...... teroid anti-inflammatory drug.
@ast
Long-term management of atopic ...... teroid anti-inflammatory drug.
@en
Long-term management of atopic ...... teroid anti-inflammatory drug.
@nl
P2093
P356
P1476
Long-term management of atopic ...... steroid anti-inflammatory drug
@en
P2093
Alexander Kapp
Ann Bingham
Flare Reduction in Eczema with Elidel (infants) multicenter investigator study group
Jean-Paul Ortonne
Mark Thurston
Nathalie Barbier
Paul C Potter
Regina Fölster-Holst
Stephen Molloy
Wayne Gulliver
P304
P356
10.1067/MAI.2002.126500
P407
P577
2002-08-01T00:00:00Z